Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma

Stopped early · Phase 1

Conditions studied: Non-hodgkin Lymphoma

In brief

The primary objective of this study is to determine the safety and tolerability of GS-0189 (formerly FSI-189) as monotherapy and in combination with rituximab in participants with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).

Key facts

Study ID

NCT04502706

Run by

Gilead Sciences

People needed

9

Starts

2020-11-17

Expected to finish

2022-03-31

Last updated by the study team

2023-06-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Alabama Comprehensive Cancer Center — Birmingham, Alabama, United States
• City of Hope — Duarte, California, United States
• Florida Cancer Specialists — Sarasota, Florida, United States
• Washington University School of Medicine — St Louis, Missouri, United States
• University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.